ARTICLE | Company News
Nektar, Takeda partner to evaluate combo therapy for cancer
April 27, 2018 7:53 PM UTC
Nektar Therapeutics (NASDAQ:NKTR) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to evaluate Nektar's NKTR-214 in combination with Takeda's TAK-659 to treat cancer. The partners will split clinical trials costs. The first trial is expected to start next half and will evaluate NKTR-214 every three weeks with once-daily doses of TAK-659 in patients with non-Hodgkin's lymphoma (NHL)...